

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>MPM BIOVENTURES 2018, L.P.</u> (Last) (First) (Middle) <u>450 KENDALL STREET</u> (Street) <u>CAMBRIDGE MA 02142</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>09/16/2020</u>	3. Issuer Name and Ticker or Trading Symbol <u>Dyne Therapeutics, Inc. [DYN]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series A Preferred Stock	(1)	(1)	Common Stock	4,215,076	(1)	I	See footnote ⁽²⁾
Series A Preferred Stock	(1)	(1)	Common Stock	224,025	(1)	I	See footnote ⁽³⁾
Series A Preferred Stock	(1)	(1)	Common Stock	83,188	(1)	I	See footnote ⁽⁴⁾
Series B Preferred Stock	(5)	(5)	Common Stock	399,867	(5)	I	See footnote ⁽²⁾
Series B Preferred Stock	(5)	(5)	Common Stock	21,254	(5)	I	See footnote ⁽³⁾
Series B Preferred Stock	(5)	(5)	Common Stock	7,893	(5)	I	See footnote ⁽⁴⁾

1. Name and Address of Reporting Person* <u>MPM BIOVENTURES 2018, L.P.</u> (Last) (First) (Middle) <u>450 KENDALL STREET</u> (Street) <u>CAMBRIDGE MA 02142</u> (City) (State) (Zip)
--

1. Name and Address of Reporting Person* <u>MPM BIOVENTURES 2018 (B), L.P.</u> (Last) (First) (Middle) <u>450 KENDALL STREET</u> (Street) <u>CAMBRIDGE MA 02142</u> (City) (State) (Zip)
--

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[MPM ASSET MANAGEMENT
INVESTORS BV2018 LLC](#)

(Last) (First) (Middle)

450 KENDALL STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[MPM BioVentures 2018 GP LLC](#)

(Last) (First) (Middle)

450 KENDALL STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[MPM BioVentures 2018 LLC](#)

(Last) (First) (Middle)

450 KENDALL STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[EVNIN LUKE](#)

(Last) (First) (Middle)

C/O MPM CAPITAL
450 KENDALL STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

1. Name and Address of Reporting Person*

[Foley Todd](#)

(Last) (First) (Middle)

C/O MPM CAPITAL
450 KENDALL STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

1. Name and Address of Reporting Person*

GADICKE ANSBERT

(Last) (First) (Middle)

C/O MPM CAPITAL
450 KENDALL STREET

(Street)

CAMBRIDGE MA 02142

(City)

(State)

(Zip)

Explanation of Responses:

1. The Series A Preferred Stock is convertible into common stock on a 3.3169-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.
2. The shares are held directly by MPM BioVentures 2018, L.P. ("BV 2018"). The general partner of BV 2018 is MPM BioVentures 2018 GP LLC ("BV 2018 GP"). MPM BioVentures 2018 LLC ("BV 2018 LLC") is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018, except to the extent of its pecuniary interest therein, if any.
3. The shares are held directly by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"). The general partner of BV 2018(B) is BV 2018 GP. BV 2018 LLC is the managing member of BV 2018 GP. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 GP, BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by BV 2018(B), except to the extent of its pecuniary interest therein, if any.
4. The shares are held directly by MPM Asset Management Investors BV2018 LLC ("MPM Asset Management"). The manager of MPM Asset Management is BV 2018 LLC. Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley are the Managing Directors of BV 2018 LLC. Each of BV 2018 LLC, Edward Hurwitz, Luke Evnin, Ansbert Gadicke, and Todd Foley disclaims Section 16 beneficial ownership of the securities held by MPM Asset Management, except to the extent of his pecuniary interest therein, if any.
5. The Series B Preferred Stock is convertible into common stock on a 3.3169-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.

Remarks:

/s/ Ed Hurwitz, managing
director of MPM
BioVentures 2018 LLC,
the managing member of 09/16/2020
MPM BioVentures 2018
GP LLC, the general
partner of MPM
BioVentures 2018, L.P.

/s/ Ed Hurwitz, managing
director of MPM
BioVentures 2018 LLC,
the managing member of 09/16/2020
MPM BioVentures 2018
GP LLC, the general
partner of MPM
BioVentures 2018 (B), L.P.

/s/ Ed Hurwitz, managing
director of MPM
BioVentures 2018 LLC,
the manager of MPM 09/16/2020
Asset Management
Investors BV2018 LLC

/s/ Ed Hurwitz, managing
director of MPM
BioVentures 2018 LLC,
the managing member of 09/16/2020
MPM BioVentures 2018
GP LLC

/s/ Ed Hurwitz, managing
director of MPM 09/16/2020
BioVentures 2018 LLC

/s/ Luke Evnin 09/16/2020

/s/ Todd Foley 09/16/2020

/s/ Ansbert Gadicke 09/16/2020

** Signature of Reporting
Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

